Background: Several associations between microsatellite instability (MSI) and other clinicopathological factors have been reported in gastric cancer, but the results have been ambiguous. This systematic review and meta-analysis investigated the relationship between MSI and overall survival and clinicopathological characteristics of patients with gastric cancer.
Introduction
Gastric cancer is still one of the most common neoplasms worldwide and is generally associated with poor prognosis 1 . Treatment outcomes may be improved by implementing tailored therapy 2 . Optimal treatment of patients with gastric cancer also entails identifying predictors of disease prognosis. Current prognostic factors used in clinical practice include tumour location, disease staging and pathological classifications, such as those of Laurén or the WHO. Two separate genomic and molecular classifications of gastric cancer have been proposed, by The Cancer Genome Atlas (TCGA) in the USA and the Asian Cancer Research Group in Korea/Singapore 3, 4 . Both classifications may serve as a guide for better understanding the biology and behaviour of this complex disease. Notably, both of these new classifications identified microsatellite instability (MSI) as a separate subgroup of gastric cancer.
For gastric cancer, the incidence of MSI varies between countries, ranging from 5⋅6 to 33⋅3 per cent 5, 6 . Associations between MSI and other clinical and pathological factors have been reported, but with ambiguous results 4,7 -14 . However, with the new molecular classifications of gastric cancer, it seems that MSI is one of the most robust subgroups of gastric cancer. The aim of this study was to review currently available data on MSI in gastric cancer, in order to assess its role in prognosis, and its relationship with other clinical and pathological factors that may influence gastric cancer treatment.
Methods

Literature search
This systematic review with meta-analysis was performed in accordance with the PRISMA statement 15 and the Cochrane Handbook for Systematic Reviews of Interventions 16 . A literature search was undertaken in PubMed, Cochrane and Ovid databases for all articles published up to January 2016 with the Medical Subject Headings (MeSH) and keywords 'microsatellite instability', 'microsatellite repeats', 'mismatch repair', 'replication error', 'stomach neoplasms', 'stomach carcinoma', 'stomach adenocarcinoma', 'stomach tumor', 'gastric carcinoma', 'gastric adenocarcinoma', 'gastric tumor' and 'gastric cancer'. The search was carried out independently by two investigators. The keywords were used in all 66 possible combinations to obtain the maximum number of articles.
Article selection
The articles were screened for the presence of the following defined eligibility criteria according to the PICO (population, intervention, comparator, outcome) format 17 . The population comprised patients with a diagnosis of gastric cancer who underwent surgical treatment without neoadjuvant therapy. Two groups for comparison were defined, based on MSI status (with more than 1 MSI marker tested). In the present analysis, subjects included in the MSI group were those with MSI-high status, whereas the microsatellite stable (MSS) group included those with either MSS or MSI-low status. The outcome of interest was overall survival. Only studies published in full text were included. Experimental studies in animal models, single case reports, technical reports, reviews, abstracts, editorials and studies in languages other than English were excluded.
Data extraction
Data were extracted by two authors, who independently reviewed and screened all eligible studies for content according to the inclusion criteria above. Data recorded included: study design, study setting (single centre or multicentre), country of origin, year of publication, sample size, demographic features, clinicopathological characteristics, total number of patients assessed in survival analysis, total number of markers and number of mononucleotides used to estimate MSI status, threshold used to assign MSI, proportion of MSI tumours, median or mean duration of follow-up, MSI and MSS groups for estimation of the pooled hazard ratio (HR), and overall survival outcomes.
Summary outcome measures
The primary outcome was influence of MSI status on the overall survival of patients with gastric cancer. Associations between demographic features as well as clinicopathological characteristics and MSI status were investigated as a secondary analysis.
Quality assessment
All eligible articles were evaluated independently by two reviewers for risk of bias according to the Quality In Prognosis Study (QUIPS) tool 18 . Risk of bias was scored as low, moderate or high for each domain, based on answers to three to six questions, for six items: study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding and statistical analysis. A final grading of low risk of bias was assigned when three or more of the six items were considered to be of high methodological quality; risk of bias was considered high when three or more of the six items were deemed to be of low methodological quality. Otherwise a moderate risk of bias was assigned.
Statistical analysis
Comprehensive Meta-Analysis software version 3.3.070 (Biostat, Englewood, New Jersey, USA) was used for meta-analysis. In pooled analyses of associations between various demographic and clinicopathological variables and MSI status, effect sizes were calculated as odds ratios (ORs) with 95 per cent confidence intervals. The HR and 95 per cent c.i. for overall survival were retrieved from each article where possible; otherwise the value was estimated according to the method of Tierney and colleagues 19 using Plot Digitizer version 2.5.1 (http:// plotdigitizer.sourceforge.net/). The pooled HR was estimated in meta-analysis.
Between-study heterogeneity was explored using the Higgins I 2 measure 20 . I 2 values of around 25, 50 and 75 per cent were considered to represent low, moderate and high heterogeneity respectively. When the I 2 value exceeded 50 per cent, the effect size for each study was calculated Full-text articles assessed for eligibility n = 65 by a random-effects model using the DerSimonian and Laird approach 16 ; otherwise, a fixed-effect model was used. A χ 2 -based Q test was also performed to check betweenstudy heterogeneity, with P < 0⋅100 considered statistically significant. Potential sources of heterogeneity were investigated in subgroup analyses. Publication bias was evaluated by visual inspection of the funnel plot for symmetry (an asymmetric plot suggested possible publication bias) and quantified by means of Egger's test; P < 0⋅050 was considered indicative of statistically significant publication bias. Where significant heterogeneity existed across studies, sensitivity analysis was performed by omitting each study sequentially to test the influence of each individual study on the pooled result.
Results
Study selection and characteristics
The initial search produced 4239 studies, of which 3002 were excluded because of duplication. After checking the relevant bibliography, three additional articles were included. The titles and abstracts of the remaining 1240 records were screened and 65 studies fulfilled the criteria for eligibility (Fig. 1) . Of 17 articles that were subsequently excluded, nine were not written in English, two were abstracts only and two contained duplicated data ( Table S1 , supporting information). Two papers 21, 22 were excluded because they tested only one MSI marker. One retrospective study 23 was excluded because the authors investigated the relationship between MSI and the expression of hMSH2 and/or hMLH1 in patients with cancer of the gastric remnant. Finally, a study 24 investigating clinicopathological and molecular features between MLH1 methylation-positive and -negative MSI gastric cancers was not included. Forty-eight studies published between 1994 and 2016, with a study interval ranging from 1980 and 2013, were included in the review (Table S2 , supporting information) 3 -5,7-10,12-14,25-62 . The total number of patients included was 18 612, ranging from 24 13 to 2959 25 per study.
Origin of studies
Five 3,26 -29 of 48 studies (637 patients, 3⋅4 per cent) were multicentre studies from the USA, Canada, Germany, Korea, Poland, Russia, Ukraine, Vietnam, the UK,
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Relative weight (%) Reference An et al. 30 Bae et al. 25 Chuiaravalli et al. 53 Cristescu et al. 4 Czopek et al. 54 Falchetti et al. 55 Fang et al. 36 Gazvoda et al. 56 Giampieri et al. 57 Inada et al. 37 Kim et al. 10 Kim et al. 5 Marrelli et al. 8 Oki et al. 14 Oliveira et al. 60 Perez et al. 13 Schneider et al. 27 Warneke et al. 62 Wirtz et al. 12 Yamamoto et al. 50 Zhao et al. 51 Overall effect 42 . As not all studies reported all variables examined in the meta-analysis, only studies reporting the variable of interest were included, in turn, for quantitative synthesis to investigate the association between MSI status and that variable.
Microsatellite instability status and survival of patients with gastric cancer
Median follow-up was 12 to 183⋅6 months; 30 studies 4 8 these values were obtained directly from the author, and in one instance 4 the author calculated values from the raw data available from the study author. The HR was estimated from a Kaplan-Meier curve in seven studies 12 -14,27,54,56,60 . Eight studies 5,10,12 -14,30,37,53 did not find a statistically significant prognostic difference, in terms of overall survival, between MSI and MSS groups. However, the other 13 studies reported that the prognosis of the MSI group was better than that of patients with MSS gastric cancer.
The pooled HR for overall survival, based on 21 studies, showed a significant benefit for patients with MSI gastric cancer compared with those who had MSS gastric cancer (HR 0⋅69, 95 per cent c.i. 0⋅56 to 0⋅86; P < 0⋅001) (Fig. 2) . Significant heterogeneity was found among the included studies (I 2 = 69⋅6 per cent, P < 0⋅001), and a random-effects model was used for meta-analysis. Sensitivity analysis was repeated by omitting each study sequentially, with no change in the primary outcome on omission of all but three of the studies 25, 30, 57 . A further sensitivity analysis omitting these three studies did not improve the HR of MSI for overall survival (HR 0⋅67, 0⋅59 to 0⋅76; P < 0⋅001).
To explore the heterogeneity, subgroup analysis was carried out according to quality of studies (high-moderate versus low), median year of publication (before 2012 versus 2012 onwards), origin of participants (Eastern versus Western countries), median sample size (less than 214 versus 214 or more), and median number of molecular markers used to detect MSI. Subgroup analysis did not substantially alter the findings regarding the prognostic role of MSI in overall survival (Table S3 , supporting information), except in the stratified analysis by median number of molecular markers used to detect MSI, which might partly explain the heterogeneity (P = 0⋅014).
Microsatellite instability status and clinicopathological characteristics in gastric cancer
To further elucidate the role of MSI in tumour progression, the association between MSI status and demographic and clinicopathological features of gastric cancer was investigated ( Table 1) .
Sex
Thirty-five studies including 14 404 patients reported available data regarding MSI status and sex. The proportion of women was 46⋅2 per cent in the MSI group and 33⋅7 per cent in the MSS group. The pooled analysis indicated that women had a significantly increased risk of MSI compared with men (OR 1⋅57, 95 per cent c.i. 1⋅31 to 1⋅89; P < 0⋅001). Significant heterogeneity was found among the included studies (I 2 = 54⋅1 per cent, P < 0⋅001), and a random-effect analysis model was used. Sensitivity analysis was repeated by omitting each study sequentially, with no change in the outcome.
Age
All selected studies reported data on MSI status and age. The weighted mean age of patients with MSI was 65⋅9 years and that of patients with MSS disease was 60⋅4 years. Seven studies, including 1605 patients, reported available data regarding MSI status and age expressed in subgroups (65 years or more and less than 65 years). The pooled analysis showed a significant association between MSI status and age 65 years or older (OR 1⋅58, 95 per cent c.i. 2⋅20 to 1⋅13; P < 0⋅001).
Laurén classification
According to the Laurén classification, intestinal-type gastric cancer accounted for 59⋅5 per cent of tumours, mixed type 6⋅3 per cent and diffuse type 34⋅1 per cent. Furthermore, 10⋅7 per cent of intestinal-type, 0⋅9 per cent of mixed-type and 2⋅9 per cent of diffuse-type gastric cancers overall showed MSI. Thirty-four studies were analysed for the association between MSI status and histological classification according to Laurén. The pooled analysis showed that the risk of MSI was greater for intestinal than for diffuse/mixed-type gastric cancers (OR 2⋅23, 95 per cent c.i. 1⋅94 to 2⋅57; P < 0⋅001).
Tumour location
Some 15⋅5 per cent of tumours were located in the upper part of the stomach, 23⋅4 per cent in the middle and 61⋅2 per cent in the lower part. Of these tumours, 9⋅5, 8⋅8 and 22⋅0 per cent respectively showed MSI. Quantitative synthesis of 36 studies including 11 101 patients showed a significant association between MSI and middle/lower gastric cancer location (OR 0⋅38, 95 per cent c.i. 0⋅32 to 0⋅44; P < 0⋅001).
Lymph node metastases
Lymph node metastases were identified in 12⋅9 per cent of patients with MSI among all studies reporting this information. Thirty-five studies reported available data regarding MSI status and lymph node metastases (N0 versus N+). The pooled analysis showed a significant association between MSI and absence of lymph node metastases (OR 0⋅70, 95 per cent c.i. 0⋅57 to 0⋅86; P < 0⋅001). Significant heterogeneity was found among the included studies (I 2 = 61⋅0 per cent, P < 0⋅001), and a random-effect analysis model was used. Sensitivity analysis with sequential omission each study did not alter the outcome.
TNM stage
Only eight studies 3, 8, 31, 32, 34, 36, 51, 62 
Quality assessment
Twenty-six studies were considered to be of high, 19 of moderate and three of low methodological quality according to the QUIPS tool 18 (Table S4 , supporting information). All studies were included in the analysis, irrespective of methodological quality, to avoid the potential risk of excluding valuable insights from the synthesis. A sensitivity analysis was conducted that evaluated the impact of removal of low-or high-quality studies on the effect sizes; the results showed that the low-quality studies did not bias the overall results.
Publication bias and sensitivity analysis
A Begg's funnel plot was used to assess the presence of potential publication bias by plotting the effect sizes calculated from individual studies examining the association between MSI status and overall survival. The funnel plot was symmetrical, suggesting the absence of significant biases (P = 0⋅482, Egger's test), even though three studies 25, 30, 57 were outside the funnel (Fig. 3) . Although found to be heterogeneous in a sensitivity analysis, these studies did not influence the pooled HRs and confidence intervals significantly, suggesting that the estimates were robust.
Discussion
In this meta-analysis, gastric cancer with MSI was associated with better overall survival than MSS disease. Overall, MSI was found in a subgroup of gastric cancers, accounting for 9⋅2 per cent of the total. MSI was associated with female sex, intestinal histological type, increasing age, N0 status, tumours located in the mid or distal stomach, TNM stage I-II disease, and with better prognosis determined by overall survival. The results are similar to those reported in previous meta-analyses 64 -66 for gastric cancer based on much smaller numbers of patients.
The formal meta-analysis of the available literature estimated the overall prevalence of MSI gastric cancer at 9⋅2 per cent. Recent genomic analysis studies 3, 4 have reported a substantially higher rate of MSI gastric cancer (21⋅7 and 22⋅7 per cent respectively). In the TCGA study, it is possible that the MSI rate is linked to the country of origin, and probably also with high-and low-risk areas of gastric cancer incidence 67, 68 . Further analysis of factors that cause MSI gastric cancer and its association with gastric cancer incidence is needed.
Patients presenting with MSI gastric cancer are older than those with MSS tumours 69 . This has to be taken into account clinically in the future, as the majority of these older patients may present with other co-morbidities and could therefore be offered less aggressive treatment. Such patients may also be under-represented in clinical trials.
Heterogeneity was substantial across the studies analysed here. One of the most important factors was laboratory methodology. A wide variety of different markers was used to investigate MSI status. Furthermore, according to the results of subgroup analysis, the number of molecular markers used to detect MSI may partly explain the statistical heterogeneity. A challenge for the future is to standardize the detection process for MSI in gastric cancer.
The present meta-analysis has some limitations. The methodology for MSI detection was not standardized among the studies. In addition, the selection of patients varied across studies according to different clinical and pathological criteria. It must also be noted that no neoadjuvant studies were included. This is especially important in the light of modern treatment where the neoadjuvant approach plays an important role. Future analyses based on neoadjuvant treatment and the effects of different types of chemotherapy in patients with MSI gastric cancer will be of interest.
